• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by STERIS plc (Ireland)

    6/12/25 4:26:54 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    DEFA14A 1 d565169ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    STERIS plc

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11.

     

     
     


    LOGO

    You invested in STERIS plc and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual General Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on July 31, 2025.

    Get informed before you vote

    View the Notice and Proxy Statement, Fiscal 2025 Annual Report, and Directors’ Report and Consolidated Financial Statements for the Year Ending March 31, 2025 online OR you can receive a free paper or email copy of the material by requesting prior to July 17, 2025. If you would like to request a copy of the material for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance and instructions on how to request directions to the meeting. At the meeting, you will need to request a ballot to vote these shares.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the

    upcoming shareholder meeting. Please follow the instructions on

    the reverse side to vote these important matters.

     

     

     Voting Items

      Board
    Recommends
     

     1.  Election of Directors

       
     

    Nominees: 

     

       

     1a. Dr. Esther M. Alegria

     

    LOGO

     

    For

     

     1b. Richard C. Breeden

     

    LOGO

     

    For

     

     1c.  Daniel A. Carestio

     

    LOGO

     

    For

     

     1d. Cynthia L. Feldmann

     

    LOGO

     

    For

     

     1e. Christopher S. Holland

     

    LOGO

     

    For

     

     1f.   Paul E. Martin

     

    LOGO

     

    For

     

     1g. Dr. Nirav R. Shah

     

    LOGO

     

    For

     

     1h. Louis A. Shapiro

     

    LOGO

     

    For

     

     1i.   Dr. Mohsen M. Sohi

     

    LOGO

     

    For

     

     1j.   Dr. Richard M. Steeves

     

    LOGO

     

    For

     

     2.  To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2026.

     

    LOGO

     

    For

     

     3.  To appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next annual general meeting.

     

    LOGO

     

    For

     

     4.  To authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law.

     

    LOGO

     

    For

     

     5.  To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2025.

     

    LOGO

     

    For

     

     6.  To approve a proposal renewing the Board of Directors’ authority to issue shares under Irish law.

     

    LOGO

     

    For

     

     7.  To approve a proposal renewing the Board of Directors’ authority to opt-out of statutory pre-emption rights under Irish law.

     

    LOGO

     

    For

     

     8.  To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

       

     

     

       

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

                        V76058-P33101-Z90123

    Get the next $STE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    More analyst ratings

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Steris with a new price target

      Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

      5/29/25 8:18:41 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam sold $477,581 worth of Ordinary Shares (1,978 units at $241.45), decreasing direct ownership by 6% to 33,760 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/17/25 4:34:39 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. Vice Pres., CFO Tokich Michael J covered exercise/tax liability with 341 units of Ordinary Shares, decreasing direct ownership by 0.77% to 43,891 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/6/25 4:35:34 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 194 units of Ordinary Shares, decreasing direct ownership by 2% to 10,762 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/6/25 4:34:53 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    SEC Filings

    See more
    • SEC Form DEFA14A filed by STERIS plc (Ireland)

      DEFA14A - STERIS plc (0001757898) (Filer)

      7/3/25 4:32:12 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by STERIS plc (Ireland)

      8-K - STERIS plc (0001757898) (Filer)

      7/3/25 4:30:29 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 11-K filed by STERIS plc (Ireland)

      11-K - STERIS plc (0001757898) (Filer)

      6/25/25 4:16:24 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    See more
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Financials

    Live finance-specific insights

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care